Regentis Biomaterials (NYSE American: RGNT) announced it has received approval from the European Notified Body to manufacture GelrinC using its next-generation solvent-free manufacturing process. This milestone supports the product’s planned commercial launch in Europe and represents a significant advancement in the company's ability to produce its cell-free hydrogel implant for cartilage regeneration.
The new manufacturing process increases production yield by approximately 400%, producing five times more product from the same manufacturing volume while improving efficiency, scalability, and occupational and environmental safety. Extensive clinical testing has validated consistent product quality and clinical performance, ensuring that the enhanced production method does not compromise the implant's effectiveness.
GelrinC, which has already received CE Mark approval in Europe, is a proprietary, cell-free hydrogel implant designed to regenerate cartilage through a minimally invasive 10-minute procedure. The product aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S., where no off-the-shelf treatment is currently available. The U.S. cartilage repair market is valued at approximately $3 billion.
Regentis plans to support commercialization through its expanding European Centers of Excellence, surgeon training programs, and collaborations with leading orthopedic institutions, including Humanitas Research Hospital in Milan. The company’s Gelrin platform technology, based on synchronized, degradable hydrogel implants, is designed to regenerate damaged or diseased tissue including inflamed cartilage and bone.
This approval is a critical step for Regentis as it prepares to enter the European market, offering a new treatment option for patients suffering from cartilage damage. The improved manufacturing process not only boosts production capacity but also enhances safety for workers and the environment, aligning with broader industry trends toward sustainable manufacturing. For the orthopedic industry, the availability of an off-the-shelf, cell-free hydrogel implant could transform standard of care for cartilage repair, potentially reducing the need for more invasive surgeries and improving patient outcomes.
Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing innovative tissue repair solutions. The company’s lead product GelrinC is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage in a controlled and synchronous process. The latest news and updates relating to RGNT are available in the company’s newsroom at https://ibn.fm/RGNT.
Forward-looking statements in this article involve risks and uncertainties, as detailed in the company’s filings with the SEC. Undue reliance should not be placed on these statements, and the company undertakes no duty to update them unless required by law.
